Product Images Losartan Potassium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 6 images provide visual information about the product associated with Losartan Potassium NDC 50090-4252 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - lbl500904252

Label Image - lbl500904252

fig 2 - losartanpotassiumfig2

fig 2 - losartanpotassiumfig2

The given text seems to show a comparison of two medications, atenolol and losartan potassium, in terms of their effectiveness in reducing the risk of fatal/non-fatal stroke in patients. It also mentions an adjusted risk reduction of 25% with p-value of 0.001. The rest of the text appears to show a graph with study months on the x-axis and RAiTI values on the y-axis. It is not possible to determine the complete context or meaning of the given text.*

fig 4 - losartanpotassiumfig4

fig 4 - losartanpotassiumfig4

The text appears to be a chart displaying data for a study comparing Losartan Potassium to a placebo in patients with an event. The chart shows the number of patients (60, 40, 20) and a risk reduction percentage of 16.1%, with a p-value of 0.022. However, without additional context or information, it is unclear what type of event is being studied or the significance of the results.*

fig 1 - losartanpotassiumfigure1

fig 1 - losartanpotassiumfigure1

The text seems to be a chart or a graph that displays the percentage of patients with the primary endpoint for two different medications, Atenolol and Osartan Potassium. It also shows an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study goes up to 66 months.*

fig 3 - losartanpotassiumfigure3

fig 3 - losartanpotassiumfigure3

This appears to be a table or chart displaying results of a study involving patients divided into categories such as age, gender, race, and medical history. The study also involved comparing two medications, losartan potassium and atenolol, and reporting the number of events and hazard ratios associated with each. However, without more context or a clearer format, it is difficult to draw meaningful conclusions from this information.*

Losartan Potassium - losartanpotassiumstrfrm1

Losartan Potassium - losartanpotassiumstrfrm1

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.